CVM
Cel-Sci Corp (CVM)
Healthcare • NYSE MKT • $1.70+6.25%
- Symbol
- CVM
- Exchange
- NYSE MKT
- Sector
- Healthcare
- Industry
- Biotechnology
- Price
- $1.70
- Daily Change
- +6.25%
- Market Cap
- $14.38M
- Trailing P/E
- N/A
- Forward P/E
- -1.85
- 52W High
- $13.48
- 52W Low
- $1.44
- Analyst Target
- N/A
- Dividend Yield
- N/A
- Beta
- 0.71
CEL-SCI Corporation, a clinical-stage biotechnology company, engages in the research and development to treat cancer and other diseases by using the immune system in the United States. The company's lead immunotherapy is Multikine, which has completed Phase III clinical trials for the potential treatment of certain head and neck cancers. It is also developing Ligand Epitope Antigen Presentation System (LEAPS) technology, a patented T-cell modulation process that stimulates the human immune system to fight bacterial, viral, parasitic infections, autoimmune conditions, allergies, transplantation rejections, and cancer, as well as to potentially treat rheumatoid arthritis. In addition, the company's LEAP product candidates include CEL-2000; CEL-4000; and CEL-5000 that are in preclinical trial…
Company websiteResearch CVM on Stk-Ai
Stk-Ai gives you screening across 100+ fundamental metrics, AI-powered analysis, target predictions, backtested signals, and portfolio tracking — all in one place.
Data shown is for informational purposes only and is not investment advice. Prices and metrics may be delayed.